PREVALENCE OF THE RHEUMATOID FACTOR AND ITS INFLUENCE ON THE CLINICAL PROFILE AND GRAVITY OF SYSTEMIC SCLEROSIS

PREVALENCE OF THE RHEUMATOID FACTOR AND ITS INFLUENCE ON THE CLINICAL PROFILE AND GRAVITY OF SYSTEMIC SCLEROSIS

PONT, ISADORA DAL; PONTES, JADY ELEN DE; SANTOS, THIAGO ALBERTO FERNANDES GOMES DOS; MARTIN, PATRICIA; AZEVEDO, PEDRO MING; SKARE, THELMA LAROCA

Pôster:

Systemic sclerosis (SSc) is a diffuse autoimmune connective tissue disease, in which cutaneous fibrosis associated with various forms of visceral involvement is identified. Serum autoantibodies are found in 80% or more of the patients; the classical are anti-centromere (ACA) and anti-topoisomerase I (anti-Scl-70). Several other autoantibodies may be present in ES, although at a lower frequency and without connotation of diagnostic markers. Rheumatoid factor (RF), found in 30 to 40% of patients.

Materials and methods

Retrospective study of 108 charts of patients with SSc from the last 20 years of the HUEMC Rheumatology Outpatient Clinic to analyze the serum IgM-FR values. Epidemiological data (age at onset of ES, race, sex, smoking, and alcohol consumption) were also collected; clinical findings (clinical form of disease, Medsger's Index, modified Rodnan's Index and findings such as Raynaud's Phenomenon, stellar scars, telangiectasia, microstomia, altered esophageal motility, pulmonary fibrosis and hypertension, myosites, myocarditis, renal scleroderma, arthralgia, arthritis and tendinopathies) and serological data from other autoantibodies (FAN, ACA, anti-Scl-70, anti-Ro, anti-RNP and anti-La). Patients with positive RF were compared to the negative RF.

Results

The prevalence of RF in the sample studied was 36.11%. The RF did not change the clinical and epidemiological profile including joint symptoms (all p=ns). Regarding the serological profile, there was a statistically significant difference in anti-Scl-70 (p = 0.02). Negative FR patients have eight times (O.R. = 8.3) more chances of having this autoantibody than the FR positive patients.

Conclusion

The prevalence of RF in ES patients was 36.11%, higher than the prevalence found in most other studies, but within the expected range for this group of patients. There was no statistically significant difference when comparing the FR positive and negative RR groups for the epidemiological and clinical profiles. Regarding the autoantibody profile, a significant statistical difference was found between the groups regarding anti-Scl-70.

Systemic sclerosis (SSc) is a diffuse autoimmune connective tissue disease, in which cutaneous fibrosis associated with various forms of visceral involvement is identified. Serum autoantibodies are found in 80% or more of the patients; the classical are anti-centromere (ACA) and anti-topoisomerase I (anti-Scl-70). Several other autoantibodies may be present in ES, although at a lower frequency and without connotation of diagnostic markers. Rheumatoid factor (RF), found in 30 to 40% of patients.

Materials and methods

Retrospective study of 108 charts of patients with SSc from the last 20 years of the HUEMC Rheumatology Outpatient Clinic to analyze the serum IgM-FR values. Epidemiological data (age at onset of ES, race, sex, smoking, and alcohol consumption) were also collected; clinical findings (clinical form of disease, Medsger's Index, modified Rodnan's Index and findings such as Raynaud's Phenomenon, stellar scars, telangiectasia, microstomia, altered esophageal motility, pulmonary fibrosis and hypertension, myosites, myocarditis, renal scleroderma, arthralgia, arthritis and tendinopathies) and serological data from other autoantibodies (FAN, ACA, anti-Scl-70, anti-Ro, anti-RNP and anti-La). Patients with positive RF were compared to the negative RF.

Results

The prevalence of RF in the sample studied was 36.11%. The RF did not change the clinical and epidemiological profile including joint symptoms (all p=ns). Regarding the serological profile, there was a statistically significant difference in anti-Scl-70 (p = 0.02). Negative FR patients have eight times (O.R. = 8.3) more chances of having this autoantibody than the FR positive patients.

Conclusion

The prevalence of RF in ES patients was 36.11%, higher than the prevalence found in most other studies, but within the expected range for this group of patients. There was no statistically significant difference when comparing the FR positive and negative RR groups for the epidemiological and clinical profiles. Regarding the autoantibody profile, a significant statistical difference was found between the groups regarding anti-Scl-70.

Palavras-chave:

DOI: 10.5151/sbr2019-551

Referências bibliográficas

• [1]

Como citar:

PONT, ISADORA DAL; PONTES, JADY ELEN DE; SANTOS, THIAGO ALBERTO FERNANDES GOMES DOS; MARTIN, PATRICIA; AZEVEDO, PEDRO MING; SKARE, THELMA LAROCA; "PREVALENCE OF THE RHEUMATOID FACTOR AND ITS INFLUENCE ON THE CLINICAL PROFILE AND GRAVITY OF SYSTEMIC SCLEROSIS", p-551-551. In: Anais do 36º Congresso Brasileiro de Reumatologia. [ISBN 978-85-212-1892-0]. São Paulo: Blucher, 2019.
ISSN 23577282, DOI 10.5151/sbr2019-551